Company intelligence / Profile preview

Chugai Pharmabody Research

Singapore, Central Singapore, Singaporechugai-pharmabody.com ↗

Ownership: Private
Employees: ~127
Development stage: Commercial

Overview

CPR has successfully contributed to the creation of SKY 59 and other antibody drug candidates as well as maximizing the value of Chugai's antibody engineering technologies[2]

Therapeutic areas: NephrologyRheumatologyImmunologyOncologyNeurologyInfectious Diseases
Modalities: Antibody drugsCyclic peptides
Industry: Pharma

Drug pipeline

1 asset

crovalimab

Commercial

Indications: PNH

Partnerships

Roche

Beyond the preview

Go deeper on Chugai Pharmabody Research.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chugai Pharmabody Research.

Explore the full profile